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A STUDY OF THE ROLE OF ACTIN POLYMERIZATION IN THE  
 
REGULATION OF VASCULAR CONTRACTILITY IN A MOUSE MODEL 
 
NIVIN OMAR 
  
ABSTRACT 
 Cardiovascular disease is the leading cause of death in the United States and 
globally. Aortic stiffness has recently been implicated as an independent risk factor and 
has attracted research efforts to prevent cardiovascular diseases. More recently, vascular 
smooth muscle cell stiffness has been proven to play an important role in aortic stiffness, 
but the precise mechanism of how smooth muscle contributes to vascular stiffness is still 
unknown. Studying VSMCs (vascular smooth muscle cells) in depth is a hot topic for 
ongoing research in this decade because, by understanding the mechanisms involved, we 
can discover novel medications to prevent cardiovascular diseases before they even 
develop. 
 
Given the importance and impact of dVSMCs (differentiated vascular smooth muscle 
cells) on cardiovascular diseases and the recent movement to the mouse as the preferred 
animal model, to take advantage of genetically modified mice that can mimic human 
diseases such as aging, hypertension and atherosclerosis in cardiovascular research, we 
need in-depth studies of dVSMCs in the mouse. Most studies on vascular smooth muscle 
have focused on cultured cells while very few have examined contractile dVSMCs. The 
freshly isolated contractile dVSMC is a better model of vivo cells than are cultured cells. 
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Thus, the purpose of this research was to develop protocols to study the contractility, 
signal transduction, and cytoskeletal regulation in small mouse blood vessels and 
contractile cells. Firstly, I developed a novel protocol to freshly isolate dVSMCs from a 
mouse aorta that are viable and respond to stimulation. This will allow us to better 
understand signaling pathways controlling dVSMCs and thus to discover targets for 
application of many therapeutic interventions to prevent cardiovascular diseases. 
Secondly, I successfully developed a modification of the differential ultracentrifugation 
protocol on mouse tissue to allow the assay of changes in actin polymerization levels in 
mouse dVSM. Thirdly, I found for the first time that contractile agonists trigger actin 
polymerization in mouse VSMCs and postulate that actin polymerization is a regulator of 
dVSM contractility in the mouse. The current literature strongly suggests that actin 
polymerization may be a valuable drug target for new cardiovascular therapeutics. 
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CHAPTER ONE 
Introduction 
 During the last two decades, great progress has been made in cardiovascular 
research, which is reflected by the 39% decrease in the cardiovascular age-specific 
mortality rate (94). Two significant research events happened in the last decade to 
strengthen our knowledge and expand our horizons for the understanding of the 
pathophysiology of cardiovascular diseases. The first one was the publication of the 
complete sequence of the mouse genome (2002), which enabled researchers to access this 
valuable information and study the function of a particular gene through genetically 
modified mice (transgenic and knockout mice). This advancement, in addition to other 
advantages of mice (e.g., ready breeders, inexpensive, and short lifespans), make the 
mouse an attractive animal model for research. The second event was the increased 
appreciation of the role of the vascular smooth muscle cell (VSMC) in cardiovascular 
diseases (2003, 2007), (64, 89). Thus, extensive research on the VSMC is warranted to 
increase our understanding of cardiovascular disease.  Additionally, as discussed here, the 
role of the VSMC in aging and aortic stiffness, are especially active areas of research that 
promise important insights into the development of cardiovascular disease. By targeting 
the pathways responsible for stiffness, we can discover novel drugs that will help 
decrease the mortality and morbidity of the number one killer worldwide: cardiovascular 
disease. With the availability of such a valuable research tool as genetically modified 
mice that can mimic human diseases such as aging, hypertension and atherosclerosis, 
there is a need to develop cellular and tissue level methods that can be used in this small 
		
2 
animal model. Thus, the primary objectives of this thesis are to develop methods for the 
study of mouse dVSMC (differentiated vascular smooth muscle cell) pathophysiology 
and to begin to determine if current concepts regarding cytoskeletal function apply to the 
mouse dVSMC. 
Cardiovascular Disease 
Cardiovascular disease is a collection of multifactorial disorders of the heart and vessels, 
including coronary artery disease, heart failure, hypertension, and stroke (71). It is the 
leading cause of death in the United States and globally (71). Every 40 seconds, one 
American dies from these diseases (71). There are two groups of risk factors for 
cardiovascular diseases: modifiable risk factors such as smoking, sedentary lifestyle, 
body weight, diet, blood pressure, and blood glucose and unmodifiable risk factors such 
as sex, age, and genetics (71). Aortic stiffness has recently been implicated as an 
independent risk factor and has attracted research efforts to prevent cardiovascular 
diseases. The American Heart Association (AHA) set a plan of increasing Americans’ 
cardiovascular health by 20% and decreasing mortality from cardiovascular diseases by 
20% by the year 2020 (71). By promoting seven modifiable risk factors, called “Life’s 
Simple 7” (i.e., no smoking, exercise, healthy diet, and body weight as well as the control 
of lipids, blood glucose, and blood pressure) cardiovascular disease incidence can be 
decreased. Hypertension is predicted to increase about 8% between 2013 and 2030 (71). 
Currently, 33% of Americans have hypertension, and about half of them do not control it 
(71). Any change in the biomechanical characteristics of blood vessels, such as aortic 
stiffness, can increase the occurrence of cardiovascular diseases like hypertension, stroke, 
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and coronary artery disease (49, 70). The pathophysiology of arterial stiffness is still 
unclear, but it was previously assumed to be solely due to changes in extracellular matrix 
(ECM); more recently, vascular smooth muscle cell stiffness has been proven to play an 
important role in aortic stiffness (85). Studying VSMCs in depth is a hot topic for 
ongoing research in this decade because, by understanding the mechanisms involved, we 
can discover novel medications to prevent cardiovascular diseases before they even 
develop. 
Mouse as a Model 
 The C57BL/6J substrain of the lab mouse C57BL/6 inbred strain was used in this 
thesis. It is the most widely used strain in the biomedical research because of its many 
advantages. It is a good model to use when studying cardiovascular diseases such as 
hypertension and atherosclerosis because it is easy to handle and inexpensive, has a short 
lifespan and short reproductive time, and serves as a good model when including age 
factors as one mouse year is equivalent to approximately 30 human years (31). In 
addition, the mouse genome sequence using C57BL/6J has been completely known since 
2002, and it resembles the human genome sequence with about 30,000 protein coding 
genes (18). Using this model, biomedical researchers can identify the role of specific 
genes in human disease by either inserting or removing a gene from the mouse genome. 
However, the small size of mouse blood vessels has been a barrier to the application of 
modern cellular and biochemical techniques to study mouse VSMC function. 
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Vascular Smooth Muscle Cells 
VSMCs are the only cells located in the tunica media of the blood vessel wall (81). Their 
contraction and relaxation help maintain normal blood pressure (104). Unlike skeletal and 
cardiac muscle cells, which contract no more than 20% (106), smooth muscle cells can 
shorten by approximately 50% of their original length, causing a dramatic shape change 
(Figure 1). 
 
Figure 1 Differentiated vascular smooth muscle cell contraction. The image shows the ability 
of dVSMC from ferret portal vein to contract to less than 50% of its resting length. Image taken 
from Vetterkind and Morgan (2012) (53) 
 
There are two distinguished phenotypes of VSMC: (1) contractile and differentiated or  
(2) synthetic, migratory, and proliferative (88) (Figure 2). Each phenotype has many 
distinctive features according to their function (Table 1).   
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 Differentiated Migratory 
Shape Spindle Cobblestone 
Function Regulate blood flow and pressure 
Embryogenesis and 
angiogenesis 
Number of 
Organelles Low High 
Migratory activity Low High 
Contractility High Low 
Proliferation Rate Very Low  High   
Dedifferentiation To migratory phenotype only in case of injury. High 
 
Table 1 Differences between vascular smooth muscle cells phenotypes. The main difference is 
that the dVSMC can contract and the migratory one can proliferate. 
 
Figure 2 Synthetic (migrating) versus differentiated VSMCs. The synthetic phenotype has 
abundant mitochondria, golgi apparatus clusters and endoplasmic reticulum for protein synthesis 
whereas the presence of contractile filaments dominate in the contractile phenotype. Image taken 
from Rensen et al. (2007)(88) 
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In the case of vascular injury, contractile VSMCs can be dedifferentiated to a synthetic 
phenotype which leads to diseases such as atherosclerosis, and heart failure (7, 76, 99). In 
primary culture as well, dVSMCs can lose the contractile apparatus and acquire more 
organelle as rough endoplasmic reticulum (RER) and Golgi apparatus and become a 
synthetic phenotype by the 7th day in the culture (114). The ability of the smooth muscle 
to shift from one phenotype to another is called “phenotype modulation” (40); this feature 
is not present in cardiac and skeletal muscle as the differentiation is terminal (76). SMCs 
(smooth muscle cells) synthesize connective tissue proteins like collagen, elastin, and 
glycosaminoglycans (52, 78, 81). This synthesis activity has been confirmed in vivo 
using an autoradiographic study (34, 93, 102). The VSMC role in atherosclerosis has 
been extensively studied. Three main contributions of SMC in atherosclerosis have been 
identified: (1) the uptake, synthesis, and metabolism of lipids by SMC (8, 9, 17, 29, 79, 
80); (2) proliferation (51, 92, 95, 100); and (3) the synthesis of ECM (46, 72, 90, 112). 
Vascular Smooth Muscle Contraction 
Normal functioning dVSMC is a crucial component for cardiovascular system 
physiology.  Disturbance in the smooth muscle cell contractile properties can lead to 
cardiovascular diseases such as hypertension through an increase in systemic vascular 
resistance (77). Genetically modified mice with vascular dysfunction exhibit 
hypertension (10, 11, 20, 67, 110). 
          Vascular smooth muscle cells contract in response to one of three stimuli: 
electrical, chemical (hormones and neurotransmitters), or mechanical (stretch or pressure) 
(Figure 1.3). Electrical stimulation will evoke the opening of the voltage-gated Ca+2 
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channels through depolarization of the sarcolemma. This depolarization will lead to an 
increase in Ca+2 influx from the extracellular space and in turn stimulate Ca+2 release 
from the sarcoplasmic reticulum (Ca+2-induced Ca+2 release, CICR). For chemical 
stimulation, the neurotransmitters or hormones bind to a specific receptor in the cell 
membrane and activate myosin. Finally, mechanical stimulation is a contractile response 
to pressure or stretch on the arterial wall and is known as the Bayliss effect or myogenic 
response (6). This effect generates a contraction either through depolarization of the 
sarcolemma and increases in intracellular calcium (23, 41) or by focal adhesion and 
cytoskeletal remodeling (24). These three stimuli develop a force through cross-bridge 
cycling between actin and myosin. Myosin activation requires the phosphorylation of its 
20-KDa light chain (LC20) by myosin light chain kinase (MLCK). Also, the availability 
of actin is regulated by actin binding proteins (53). All Ca2+-dependent pathways of 
smooth muscle contraction are mediated by an increase in intracellular Ca2+ that will 
bind with calmodulin to form a Ca2+-calmodulin complex and activate MLCK. For 
Ca+2-independent pathways, there are numerous kinases that are able to phosphorylate 
MLC independently of Ca2+. Among them are integrin-linked kinase (26), Rho-
associated protein kinase (ROCK) (60), and zipper-interacting protein kinase (ZIPK) 
(72). In addition to the phosphorylation of MLC, these kinases inhibit myosin 
phosphatase to enable smooth muscle contraction at a constant Ca2+ level (53). 
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Figure 3: Smooth muscle contractile stimuli and signaling pathways. The three stimuli of 
VSMCs (chemical, mechanical, and electrical) can cause contraction of dVSMC either through 
Ca2+-dependent (myosin activation) or Ca2+- independent (increase in actin availability) 
pathways. Image taken from Vetterkind and Morgan, 2012 (53) 
 
Contractile stimuli  trigger signaling pathways that control the availability of actin and/or 
myosin activation i.e. cross-bridge cycling or cytoskeletal and focal adhesion remodeling 
(11) (Figure 4). 
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Figure 4 Detailed, recently discovered, signaling pathways that regulate vascular smooth 
muscle contraction. Pathways #1 and #2 increase the activation of myosin while pathway #3 
increases actin availability. Pathway #4 involves cytoskeletal and focal adhesion remodeling. 
Image taken from F.V. Brozovich et al. 2016 (11). 
 
These pathways are categorized into four pathways with four different mechanisms. The 
first pathway involves an increase in myosin activity by changing the phosphorylation of 
LC20 as previously mentioned. Examples of this pathway are: the phenylephrine agonist 
and KCl physiologic saline solution (KCl PSS) which both cause depolarization of 
smooth muscle cells that leads to a surge in the intracellular calcium and the 
phosphorylation of LC20(1, 50). The second pathway inhibits myosin phosphatase either 
by activation of the small GTPase RHO/ROCK (101) or ZIPK activity. The third 
pathway increases the actin availability to interact with myosin through regulation of 
actin binding proteins. This pathway involves extracellular signal regulated kinase 
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(ERK1/2), calponin (CaP), and calmodulin (CaD). The recently discovered final pathway 
involves cytoskeleton and focal adhesion remodeling to regulate force generation and 
maintenance (55, 108). Specifically, that PE (phenylephrine) and, in the lung, 
acetylcholine work through pathways 1, 3, and 4. 
dVSMC Role in Vascular Stiffness 
The regulation of blood pressure and flow in the cardiovascular circulation depends on 
normal functioning resistance arteries, which is why any changes in this vasculature, such 
as stiffness, can cause cardiovascular diseases (19).  Recently, arterial stiffness had been 
identified as an independent risk factor for cardiovascular diseases. It precedes and 
predicts negative cardiovascular outcomes such as hypertension, myocardial infarction, 
and heart failure (49, 68, 103). 
    Most of the previous studies of vascular mechanics have identified that the ECM plays 
a significant role in vascular stiffness (104). However, recent studies have discovered that 
the actin cytoskeleton also contributes to the aging-associated increase in stiffness of  the 
aortic smooth muscle cell, (85, 98). The precise mechanism of how smooth muscle 
contributes to vascular stiffness is still unknown and thus requires further research. By 
understanding the molecular mechanisms of arterial stiffness, targets for novel 
therapeutic intervention to prevent cardiovascular diseases will be identified. In addition, 
previous studies have shown that the VSMCs could contribute to vascular stiffness by 
increasing resting tone (37), or by inducing ECM proteins synthesis and 
metalloproteinase (MMP) activity (75). Increased VSMC stiffness was recently revealed 
to be an important component of aortic stiffness with aging (85). It was found that there 
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is increased expression of β1-integrin and α-smooth muscle actin in VSMC of the aged 
aorta, which may contribute to and play an important role in VSMC stiffness. It was 
recently discovered in our lab that the FA (focal adhesion) of VSMC (Src-FAK signaling 
complex (sarcoma-focal adhesion kinase)) plays a significant role in aortic stiffness (96).  
dVSMC Cytoskeletal Structure 
The cytoskeleton consists of three main types of filaments—microtubules, intermediate 
filaments, and microfilaments (actin)—in addition to accessory proteins that provide 
inter- and intracellular connection (97). In contrast to the cardiac and skeletal 
cytoskeleton, the smooth muscle cytoskeleton does not have a regular pattern. Actin (42 
kDa) constitutes up to 20% of the overall protein in dVSMC (55). There are two main 
categories of actin in dVSMC: contractile actin (alpha smooth muscle actin isoform), 
which interacts with myosin, and cytoplasmic or cytoskeletal actin (non-muscle gamma 
and beta actins isoform), which does not interact with smooth muscle myosin II (107). 
The predominant actin isoform in vascular smooth muscle is the alpha isoform, 
constituting approximately 60% of actin in large vessels, while beta isoform forms about 
20% (27). For a cultured cell, the contractile smooth muscle loses alpha actin as it 
changes to a synthetic phenotype (27). Our lab previously discovered that the γ-actin 
isoform is located in the cortical cytoskeleton (33) and is the most dynamic actin with 
respect to polymerization/depolymerizztion in response to an α-agonist (PE) (55). In 
addition, the alpha actin filaments are found to be either longitudinal or perpendicular to 
the cell axis and are associated with the myosin to form the contractile apparatus (33). 
The beta actin is found around the dense bodies (DBs) in the cytoplasm and focal 
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adhesions (FAs) at the membrane (33), (Figure 3). The cytoplasmic dense bodies connect 
the contractile apparatus to the non-muscle cytoskeleton. The dense plaque (FA) (14) is a 
complex collection of proteins (structural and signaling) that connects the actin 
cytoskeleton to the ECM (108). Integrin promotes bidirectional signal transduction from 
the cell to the ECM and vice versa (45). The molecular mechanism of cytoskeletal 
remodeling in the VSMC’s response to contractile stimuli is not completely clear yet.  
The plasticity of actin cytoskeleton plays an important role in the airway and vascular 
differentiated smooth muscle (38, 55). The contractile agonist stimulation of dVSMC can 
lead to cortical stiffness and remodeling in the contractile and non-contractile actin 
cytoskeleton (2, 43, 55). Previous research on the airway smooth muscle shows that the 
actin branching factor N-WASP (Neuronal wiskott-aldrich syndrome protein) is 
important for smooth muscle contractility and actin remodeling (109). However, its effect 
in dVSMC has not yet been studied. Our lab previously found that the actin elongation 
factor VASP (Vasodilator-stimulated phosphoprotein) is an important factor for vascular 
smooth muscle contraction and actin remodeling (56). Therapeutic interventions targeting 
the VSMC’s cytoskeleton may offer promise for many cardiovascular diseases as 
hypertension and aortic stiffness. 
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Figure 5 Cytoskeleton Structure of dVSMC. The image shows the three main components of 
the eukaryotic cytoskeleton: microtubule, intermediate filament, and microfilament. It also shows 
how the actin cytoskeleton is connected to the ECM through FA. Image taken from 
Yamin and Morgan (2012) (107). 
 
Actin Polymerization 
Actin polymerization and depolymerization can control the airway and blood vessel 
contractile force, compliance, and diameter (30, 35, 67). Actin polymerization can take 
place in three forms: a nucleation, an elongation, and branching (107). Actin, the most 
plenteous protein in eukaryotic cells, has two forms—either a filamentous double helical 
polymer (F-actin)  (39), or a globular monomer (G-actin) (48). The G-actin monomer can 
spontaneously form F-actin polymer when it exceeds its critical concentration (CC) ~ 
8 µg/ml (83). Approximately 30% to 40% of total actin in SMC is present as G-actin 
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while in skeletal muscle it constitutes only 11% to 13% (21). This makes the F/G-actin 
ratio in smooth muscle 1:1 or 2:1 compared to 8:1 or 9:1 in skeletal muscle, with a large 
G-actin pool of unknown function in the smooth muscle (21). The function of this high 
level of actin in smooth muscle is not yet clear (5). An abundance of actin binding 
proteins (ABP) exist in the cell—about 162 proteins—and some regulate actin 
polymerization and depolymerization (87). ABP include actin depolymerizing factor 
(ADF)/cofilin, Arp2/3 complex (Actin related proteins 2/3), capping proteins, calponin, 
caldesmon, profilin, and sequestering proteins. Previous research on the airway smooth 
muscle shows that the actin branching factor (N-WASP) is important for smooth muscle 
contractility and actin remodeling (109).  
 
Thesis Rationale 
It has been recently appreciated that dVSMCs play an important role in aortic vascular 
stiffness and subsequent cardiovascular disease development, such as hypertension and 
atherosclerosis. The contractile ability of dVSMCs also has a well-established role in 
determining stress levels in resistance vessels and subsequent changes in blood pressure. 
The mechanism of how dVSMCs contribute to stiffness is not completely understood, 
and extensive research on dVSMCs is required. Most studies on vascular smooth muscle 
have focused on cultured cells while very few have examined contractile dVSMCs. Our 
lab (Morgan Lab) is one of the few labs working on dVSMCs, mainly from ferrets. The 
freshly isolated contractile dVSMC cell is a better model of vivo cells than are cultured 
cells.  
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 Recently a change has occurred in animal model preference to the mouse due to 
its many advantages, as previously mentioned, especially the opportunity to use 
transgenic mice. Thus, the purpose of this thesis was to develop protocols to study the 
contractility, signal transduction, and cytoskeletal regulation in small mouse blood 
vessels and contractile cells. I developed a novel protocol to freshly isolate dVSMCs 
from a mouse aorta that is viable and responds to stimulation. This will allow us to better 
understand signaling pathways controlling dVSMCs and thus to discover targets for 
application of many therapeutic interventions to prevent cardiovascular diseases. In 
addition, I successfully developed a modification of the differential ultracentrifugation 
protocol on mice tissue to allow the assay of changes in actin polymerization levels in 
mouse dVSM. Thirdly, I found for the first time that contractile agonists trigger actin 
polymerization in mouse VSMCs and postulate that actin polymerization is a regulator of 
dVSM contractility in the mouse.  	
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CHAPTER TWO: Materials and Methods 
Ethical Approval 
The conduct of all processes is based on the policies of the Institutional Animal Care and 
Use Committee of Boston University. The treatment of animals was according to the 
instructions in the NIH Guide for the Care and Use of Laboratory Animals. In addition, 
the utilization and acquisition of these animals conformed to domestic laws. 
 
Animal and Mouse Tissue Preparation 
Young C57BL/6J male mice (3 months ± 2 weeks, N = 20, Jackson Lab strain, MA) were 
euthanized via the inhalation of an overdose of isoflurane in a ventilation hood. The 
whole aorta was quickly cut out and cleaned by frequent dipping in six different beakers 
filled with Krebs solution to remove any blood within the vessel, which can damage and 
irreversibly contract VSMC (13). The aorta was then carefully dissected in a dissection 
dish with an oxygenated (95% O2 – 5% CO2) Krebs solution (composed of, in mM, 120 
NaCl, 5.9 KCl, 25 NaHCO3, 11.5 Dextrose, 2.5 CaCl2, and 5.36 MgCl2; pH was 7.4) to 
clear away any fat or connective tissue. The arch and the abdominal part of the aorta were 
removed. To prevent damage to the VSMC, the Krebs solution was changed if there was 
excessive blood in the dissecting dish or 30 min of dissection had passed. The Krebs 
solution was made fresh on the day of the experiment. After dissection, the thoracic aorta 
(~ 9 mm length) was weighed (weight ranges between 6 and 10 mg) and cut into four to 
six pieces according to the weight for further single dVSMC isolation. However, for 
differential ultracentrifugation, the thoracic aorta was cut into two rings of 4 mm each. 
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Biomechanics Measurements 
 Only 2 to 3 laboratories have been able to implement techniques to measure ex vivo 
contractility from the very small mouse blood vessels. The technique I have used 
involved two triangular wires that were carefully passed through the lumen of the aorta 
ring using forceps without over-stretching or piercing the vessel, as this could damage the 
smooth muscle cells. Each ring was then attached to a force transducer and stretched to 
1.4 times its resting length. This has previously been determined to place the muscle at 
the optimal length for force production. In an organ bath (Myobath II, WPI, Sarasota, FL) 
pre-warmed to 37°C and filled with 50 cc of bubbling oxygenated (95% O2 – 5% CO2) 
Krebs solution (Fig. 1) the rings were then set to equilibrate for one hour. Lab Chart 
software (AD Instruments, CO) was used to analyze data. Tissues were then stimulated 
for 15 minutes with 51 mM KCl (51 mM of NaCl in Krebs solution replaced by KCL; 
KCL Krebs) to test for viability; ring contractions of approximately 0.5 g were 
considered viable and healthy. Aorta rings were washed three times with the Krebs 
solution and then left to relax for 1 hour. 10 µM PE was added to some of the rings for 10 
minutes, after which the rings were quickly frozen by immersing them into a freezing 
solution of dry ice–acetone slurry and 10 mM DTT (Dithiothreitol, Fisher Scientific, NJ). 
Control and PE stimulated rings were kept at –80°C for further use in differential 
ultracentrifugation. 
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 Figure 6 Myobath II - 4 mm long mouse thoracic aorta ring attached to the vascular holder in 
the organ bath filled with 50 cc oxygenated (95% O2 – 5% CO2) Krebs solution to test viability. 
 
 dVSMC Isolation 
Cells with normal function and pharmacological response were freshly enzymatically 
isolated successfully for the first time from the thoracic aorta of mice, following 
previously published methods (25, 62) ; some adjustments were made to get longer and 
more dissociated cells for the mice tissues. Aorta pieces were carefully transferred with 
forceps to a 125 ml siliconized flask (Sigmacote, Sigma-Aldrich, USA) containing 7.5 ml 
of a digestion solution (1.35 ml collagenase, 1.84 ml elastase, 0.0975 ml trypsin inhibitor, 
and 4.1825 ml Hanks BSA). For the digestion solution, first Hanks was prepared 
(composed of, in mM, 137 NaCl, 5.4 KCl, 0.42 NaH2PO4, 10 Hepes, and 5.55 Glucose, 
with the pH of 7.4 adjusted with 10 N NaOH) (Table 1) and Hank’s BSA, which is Hanks 
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with 0.2% BSA (7.5% bovine albumin solution by Life Technologies, Inc.). Second, the 
enzymes were added, and the following solution was kept on ice: 5.8 mg/2.2 ml of 
Hank’s BSA for type II collagenase (385 u/mg, Worthington), 4.56 mg/4 ml of Hank’s 
BSA for elastase (3.85 u/mg, Roche Applied Science), and 10 mg/0.5 ml of Hank’s BSA 
for soybean trypsin inhibitor (Sigma). The flask was kept under an atmosphere of 100% 
oxygen and secured in a water bath (shaking rate 104 cycles/min and a temperature of 
approximately 34°C) for 60 minutes. The flask was well siliconized; if a drop of water 
inside the flask formed a bead and did not spread all over the flask, it indicated that the 
siliconized flask was very hydrophobic.  
 
After incubation, the tissue pieces were filtered on a nylon mesh (Spectra/Mesh 
Polypropylene Filters, pore size 0.5 mm, 39% open area, thickness 610 µm; Spectrum 
Laboratories, Inc., Rancho Dominguez, CA) and poured into a second siliconized flask 
over ice. The remaining tissue pieces on the mesh were then washed with 7.5 ml Ca+2 
and Mg+2 free Hanks and 0.2% BSA. The filtrate containing the dissociated cells was 
then poured carefully over glass coverslips (12 mm diameter, Electron Microscopy 
Sciences, Hatfield, PA) in a 24-well tissue culture plate (Sarstedt Inc., Newton, NC) on 
ice and under an atmosphere of 100% oxygen. 3 ml of filtrate per well for 5 wells were 
used; one of the wells was used to test the viability, and the other 4 were labeled as 
control or intervention with PE. Rough in- and- out pipetting was avoided as it can cause 
damage to the cells. The cells were left for 30 minutes to settle and adhere to the 
coverslips. Then, BSA Ca+2 and Mg+2 Hank’s (Hank’s BSA + 1mM CaCl2 and 1.2 mM 
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MgCl2) was gradually added to the coverslips over 40 minutes to prevent cell damage 
(44, 111). I tested one coverslip with a Nikon Diaphot microscope 10 X magnification at 
room temperature using 51 mM KCl HBSS to confirm the viability of the cells by 
shortening. The remaining coverslips were put at room temperature and under 100% O2 
inside the container for testing with PE. Hank’s BSA containing 300 mM sucrose was 
added to the other coverslips to increase tonicity, prevent cell shortening at the cross-
bridge level (15) when the agonist stimulus was used, and provide a more relaxed cell for 
clear imaging. Previous studies have shown that the Hanks sucrose has no effect on the 
dVSMC resting cell length (3) or intracellular calcium level (54). After 10 minutes of 
adding sucrose, PE (10 µM) was added to some of the coverslips before waiting an 
additional 10 minutes. 
 
In the cell isolation protocol, I tried to decrease the elastase to 40% less than the 
previously used protocol, but I ended up with fewer cells. I then tried to reduce the 
collagenase by 20%, but the cells did not look healthy, and I noticed a lot of disintegrated 
cells. The best results I got involved decreasing the elastase by 20%. I only used one 
digestion solution instead of two and, with this change, got a good number of viable, long 
dissociated cells which contracted approximately 40% – 50% of their length with the 
addition of KCL. 
Cell Staining  
All coverslips were fixed with 4% paraformaldehyde for 20 minutes in a 100 mM sodium 
phosphate buffer (pH 7.4). Cells were permeabilized using 0.1% Triton X-100 in 1% 
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Hank’s BSA for 10 minutes and blocked with 0.05% Triton X-100 and Hank’s BSA for 
30 minutes with gentle shaking. Cells were stained for 15 minutes with DNase I (6uM 
Alexa Fluor 488, Invitrogen, Eugene, OR) for G-actin, phalloidin (Alexa Fluor 568, 
1:100 dilution, Invitrogen) for F-actin, and DAPI (2-(4-Amidinophenyl)-6-
indolecarbamidine dihydrochloride, 10 mg/1 ml, Sigma) for the nucleus; these three 
stains were added to Hanks with a final concentration of 25% glycerol. The specificity of 
phalloidin to F-actin and DNase I to G-actin was previously studied and used  to 
quantitate and localize F-actin and G-actin (58). From this step on, the coverslips were 
kept in a light-tight container. After that, the cells were washed three times with Hanks 
for 5 minutes each, with gentle shaking, and once with distilled water to remove any salt 
precipitate from Hanks. Then the coverslips were mounted with FluorSave (Calbiochem) 
and left overnight. Only healthy and viable cells identified by their firm attachment to the 
glass coverslips were analyzed (12). 
 
Computer Analysis and Microscopy 
F/G Ratio 
The analysis of the F/G ratio used here is modified from previously published methods 
(55). The analysis was carried out using a Nikon Eclipse TE 2000-E inverted microscope, 
provided with a Nikon Plan Apochromat 60 X (NA 1.4) oil-immersion objective and a 
charge-coupled device camera (Cool SNAP HQ2, photometrics), and using filters 
optimized for double-label experiments. The neutral density (ND) was kept constant 
throughout the analysis (ND8 in the way of the light and ND4 away). Exposure times for 
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F-actin and G-actin were kept the same for all images in one experiment. Approximately 
50 µm long cells were chosen for the analysis. 
 
NIS-Element AR 3.2 software (Nikon) was used to get the F/G ratio by tracing the entire 
cell using the region of interest (ROI); the nuclear region was then excluded from the 
analysis. For each ROI, I found the ROI statistics for the red channel (F-actin, Phalloidin) 
and green channel signals (G-actin, DNase) and then calculated the ratio by dividing the 
average intensity of the red channel by the average intensity of the green channel (Fig. 7). 
 
 Figure 7 F/G ratio using ROI statistics. RGB (red, green, and blue) image for freshly isolated 
mouse dVSMC shows (A) F-Actin stain (Alexa Fluor 568 Phalloidin) and (B) G-Actin stain 
(Alexa Fluor 488 DNase I). The whole cell was traced using region of interest (ROI), then the 
nuclear region was excluded, and the average intensity for G-Actin calculated. In addition, (C) 
shows the DAPI stain for the nucleus and (D) the merged image. 
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Deconvolution  
The Blurring of the sampled image is caused by the convolution of the light recorded 
from each of a series of planes (z-layers) of the specimen with the spread of light 
radiating outside the focal plane from those positions. Deconvolution is a mathematical 
technique to remove the light outside of the focal planes from the set of z-layers taken 
with the fluorescence microscope. The algorithm utilized in the process of deconvolution 
is a constrained iterative–maximum-likelihood estimation algorithm originally known as 
the Richardson-Lucy algorithm (42, 61, 74). Z-stacks were acquired using a Nikon 
Eclipse TE 2000=E inverted microscope provided with a Nikon Plan Apochromat 60 X 
(NA 1.4) oil-immersion objective. The images were recorded by a charge-coupled device 
camera (Cool SNAP HQ2, photometrics) with NIS-Element Advanced Research 3.2 
software (Fig. 8). 
 
		
24 
 
Figure 8. Deconvolution (A) Non-deconvolved phalloidin (Bottom, F-Actin, red) and DNase-I 
(Top, G-Actin, green) stained single mouse dVSMC (B) Deconvolved image by removal of out-
of-focus blur from a z-stack. 
 
Differential Ultracentrifugation for F/G Actin Ratio 
The protocol applied here was previously published (55) and formerly modified from the 
manufacturer’s instructions (Cytoskeleton, Denver, CO). The protocol was adjusted to be 
suitable to use for the restriction in amount and size of mouse tissue. To make 
homogenization easy and fast, 3 aorta rings (approximately 8 mg wet weight) were 
removed from –80°C and put on ice for 10 to 15 minutes. Using clean forceps, the strips 
were then taken out and dried on Kimwipe and returned to –80°C for 1 to 2 hours. After 
that, they were homogenized on ice by hand in a glass homogenizer tube (Kimble Kontes, 
Vineland, NJ) containing 80 µl of cold lysis buffer; 50 mM PIPES (PH 6.9), 50 mM 
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NaCl, 5 mM MgCl2, 5 mM EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-
tetraacetic acid), 5% (vol/vol) glycerol, 0.1% Nonidet P-40 (NP-40), 0.1% Triton X-100, 
0.1% Tween 20, 0.1% 2-mercapto-ethanol, 0.001% Pluronic with 100 mM ATP 
(Adenosine 5´- Triphosphate Disodium Salt, Grade II, minimum 99%, Sigma-Aldrich, 
MO, USA) and a 1/20th cocktail of protease inhibitor (0.4 mM Tosyl arginine methyl 
ester, 1.5 mM Leupeptin, 1mM Pepstatin A, 1M Benzamidine, Cytoskeleton, Inc., CO, 
USA). ATP and a protease inhibitor were added fresh on the day of the experiment. Then 
the homogenized samples (approximately 60 µl) were incubated at 37°C for 10 minutes 
in ultracentrifuge tubes (1.5 ml polycarbonate tubes from Beckman # 357448 and an 11 
ml spacer). They were centrifuged at 150,000 g (62,000 rpm (Revolutions per minute)) at 
37°C for 1 hour using a pre-warmed TLA-110 rotor and placed balanced in a Beckman 
Coulter Optima TLX Ultracentrifuge (Fullerton, CA), producing F-actin as a pellet while 
G-actin remained in the supernatant component. The supernatant was gently removed 
without perturbing the pellet into a new tube, which was kept on ice. The pellet was 
resuspended with the same amount of a centrifuged lysis buffer (approximately 60 µl) of 
ice-cooled distilled water having 10 µM cytochalasin D (SIGMA-ALDRICH, MO). The 
pellet was broken down to detach the F-actin via pulverization with pipetting up and 
down (100 µl pipette) and left on ice for 1 hour, vortexing every 15 minutes for 1 minute. 
Resuspended solutions were centrifuged in a table-top microfuge at 2,300 g (2.3 rcf 
(relative centrifugal force)) for 5 minutes at 4°C. From this step, the F-actin was obtained 
as a second supernatant. The loading buffer (for 10 ml: 2% glycerol (2 ml), 4.4% SDS (2 
ml), 300 mM Tris (6 ml), 125 mM DTT (0.1928g), and 10 ml distilled water) was added 
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to dilute the samples and then boiled for 5 minutes. NEM (N-Ethylmaleimide, 2.5% 
NEM and 33% BPB-saturated glycerol) was added to the samples, and then all samples 
were spun in a table-top centrifuge and incubated at room temperature for 20 to 30 
minutes before storing at –80°C for further analysis with sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. 
Gel Electrophoresis and Western Blot 
The day before running the western blot, I ran the SDS-PAGE gel to separate proteins 
according to their molecular weight. According to the previously published method (57), 
I spun thawed samples and prepared the 10% separating gel as follows: for one gel mix 
(3.35 ml DI H2O, 2 ml lower gel buffer (Tris-HCL PH 8.8, SDS 0.4% (W/V)), 2.65 ml of 
30% acrylamide: 0.8% bis-acrylamide W/V solution and just before pouring the gel into a 
minigel glass, adding 40 µl of 10% ammonium persulfate (APS) and 4 µl 
tetramethylethylenediamine (TEMED, BioRad Lab Inc., Hercules, CA)). For one gel, 4.5 
ml of this mixture was added into the minigel glass (1 mm, Biorad apparatus, Hercules, 
CA). Then 1.5 ml of DI H2O was added on the top of the gel to make the surface flat. The 
gel was left to polymerize for 30 minutes. After that, the water was poured out, and 1.5 
ml of stacking gel (1.5 ml DI H2O, 0.625 ml upper gel buffer (Tris-HCL PH 6.8, SDS 
0.4% (W/V)), 0.375 ml acrylamide (30%), 15 µl 10% APS, and 5 µl TEMED) was 
poured on the top of the separating gel with the insertion of a well-forming comb and left 
to polymerize for approximately 15 minutes. Thereafter, the comb was gently removed. 
The minigel glass without the casting stand was put in the running apparatus filled with a 
1X running buffer (25 mM Tris, 0.192 M glycine, 0.1 % SDS), and the wells were 
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washed using a syringe. I loaded 15 µl of each sample into the wells with a protein 
marker lane to separate the lanes between samples. The running apparatus was then 
sealed with its cover containing an electrical lead. This was connected to a voltage cable 
and run at 250 Watts, a constant current 35 mA, and 200 V for 45 minutes to 1 hour, until 
the tracking dye reached the base of the gel. I prepared the sandwich to transfer separated 
proteins from the gel into the nitrocellulose membrane from the bottom up. Two sheets of 
blotting paper were immersed in Anode I buffer (0.3 M Tris, 10% methanol, pH 10.4 – 
100 ml), one sheet of blotting paper was immersed in Anode II buffer (25 mM Tris, 10% 
methanol, pH 10.4 – 100 ml), nitrocellulose membrane (Whatman Florham Park, NJ) was 
soaked in an Anode II buffer gel, and two sheets of blotting paper were soaked in a 
Cathode buffer (25 mM Tris, 40 mM glycine, 10% methanol, pH 9.4 – 100 ml). All 
sheets measured 7 x10 cm and were presoaked in the corresponding buffer for 10 to 15 
minutes before making the sandwich. All air bubbles were removed from the sandwich 
by rolling a test tube gently over the stacked sandwich. The sandwich was placed in a 
semi-dry transfer chamber (Hoefer SemiPhor) and run at 15 V and 120 mA for 90 
minutes per gel. After transferring the finished membrane, it was stained with Ponceau S 
red stain to confirm protein transfer by visualizing the wanted bands in the expected kilo 
Dalton (KD) range. Then the membrane was washed with DI H2O many times to remove 
the stain and was cropped and placed in an Odyssey Blocking Buffer (Licor Bioscience, 
Lincoln, NE) for 1 hour with gentle shaking on a rotating shaker. The membrane was 
secured in a bag with a primary antibody (Actin (Cytoskeleton) rabbit polyclonal) diluted 
1:1000 in 1X Tris buffer saline with Tween (TBST) (17.5 g NaCl, 2.424 g Tris, 1000 ml 
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DI H2O, pH 7.4 and 1 ml Tween) and incubated overnight on a rotating shaker at 4°C. 
The next day, the membrane was washed with TBST 4 times for 5 minutes each, then 
incubated with the secondary antibody (goat–antirabbit, LiCOR) diluted 1:1000 in TBST, 
sheltered from light, and rocked for 30 minutes. The membrane was rinsed 4 to 6 times 
again for 5 minutes each in TBST. Odyssey Infrared Imaging System (LiCOR 
Bioscience, Lincoln NE, software version 0.3) was used for the quantitative densitometric 
analysis of F- and G-actin bands. 
Statistics 
All values given in the text are means ± standard error. Differences between means were 
evaluated using a two-tailed student’s t-test. The differences were considered statistically 
significant if the p-value < 0.05. In addition, n values represent numbers of animals and 
cells used in each experiment. 
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CHAPTER THREE: Results and Discussion 
Results 
Development of dVSMC Isolation for Mouse Model                 
The protocol used here was modified from the lab’s previous protocol to produce, for the 
first time; healthy, contractile, freshly dissociated mouse vascular smooth muscle cells. 
The C57 black 6J (C57 BL/6J) inbred mouse strain was used as it is a good breeder, 
inexpensive, with a long life span (2–3 years), its entire genome has been sequenced, and 
it can be used in cardiovascular research. This strain has a high vulnerability to diet-
induced obesity, atherosclerosis, and type-2 diabetes. Eight different genes (Ath 1 to Ath 
8) have been identified as the cause of various atherosclerotic aortic lesions in this strain.  
 
 I separately titrated the enzyme concentrations and the conditions to get viable 
single cells of dissociated, relaxed, and long dVSMCs from the mouse thoracic aorta that 
were contracted by approximately 40% to 50 % of the original length with the addition of 
51 mM KCl HBSS. To obtain this result, the elastase concentration was decreased by 
20% (3.85 u/mg, Roche Applied Science, 4.56 mg/4 ml Hank’s BSA) from the 
previously published ferret aorta method (55) . In order to show that this was optimal, the 
elastase concentration was separately reduced by 40%, but the quantity of cells produced 
was too small. The titration of the concentration of collagenase (385 u/mg, Worthington) 
above or below the concentration used for the ferret aorta resulted in unhealthy cells. The 
ferret aorta protocol included collecting cells for both the first and the second digestion. 
This was not possible with the mouse tissue, as the very small total amount of tissue in 
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the mouse yields very few cells in the second incubation. Sucrose was utilized to provide 
more relaxed cells for clear imaging. 
PE Increases Actin Polymerization in dVSMC                  
For the first time, the effect of α-agonist PE was tested on live mice aortic isolated cells. 
Our lab had previously tested this effect on ferret tissue (55), and the results showed a 
significant increase in actin polymerization with PE (10 µM) stimulation. Two methods, 
differential ultracentrifugation and co-staining of freshly enzymatically isolated smooth 
muscle cells, were used here to assess the effect of the contractile agonist on actin 
polymerization. Both methods showed that PE increases actin polymerization. First, for 
freshly isolated dVSMC, the F/G ratio was calculated by fixing and co-staining the cells 
with fluorescently labeled Phalloidin (F-actin, red) and DNase I (G-actin, green). The 
F/G ratio was calculated by dividing the Phalloidin by DNase I signal using ROI statistics 
to get the quantitative data. PE (10 µM, for 10 minutes) significantly increased the F/G 
ratio compared with that of unstimulated dVSMC (P ˂ 0.05), as shown in Figure 9. 
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Figure 9 PE increases F/G ratios from mouse aorta cells as measured using the ROI (region of 
interest) method. F/G ratios of freshly isolated dVSMC with and without PE stimulation. P < 0.05 
(P 0.0015), two-tailed t-test. The graph shows averages from five independent experiments (n = 5 
mice; 40 cells control and 44 cells PE stimulated). Average is ± SE. 
Second, using differential ultracentrifugation, the protocol here was used for the first time 
on mouse tissue (see Figure 10). Because of the small weight of the thoracic aorta of the 
mice, before conducting each experiment, I collected three viable thoracic aorta rings 
from two mice (approximately 8–10 mg) for each control or PE stimulation and froze 
them at -80˚C. To make the protocol works optimally on mouse tissue, the tissue 
homogenization was done on ice; the ATP was prepared and stored according to standard 
protocols and freshly added on the day of the experiment, and the cytoskeleton’s protease 
inhibitor cocktail was used.  
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Figure 10 Differential ultracentrifugation protocol used for mice tissue 	
The quantitative densitometric analysis of F- and G-actin bands for control and PE-
stimulated aortic tissue using Odyssey Infrared Imaging System shows an obvious  
increase in the F/G ratio with PE stimulation compared to the control (see Figure 11).  
		
33 
Subsequent experiments by Dr. Singh in the Morgan lab have shown that PE causes a 
statistically significant increase in the F/G ratio. 
 
 
 
 
Figure 11 F/G Ratio using Differential ultracentrifugation of mice aorta homogenate shows 
an increase in actin polymerization with PE stimulation. A. Immunoblot of F- and G-actin in 
unstimulated and PE (10 µM)-stimulated mice thoracic aorta strip homogenate. B. Densitometry 
of actin bands presented as F/G ratios.  Three aorta rings were pooled to perform one 
ultracentrifugation assay. 
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Discussion 
Development of dVSMC Isolation for Mouse Model 
Given the importance and impact of dVSMCs on cardiovascular diseases and the recent 
movement to the mouse as the preferred animal model in cardiovascular research, we 
need in-depth studies of dVSMCs in the mouse. In this work, I developed a modified 
method to enzymatically isolate viable and contractile dVSMCs for the first time from 
the thoracic aorta of mice. The method provides a good number of functionally and 
pharmacologically normal cells. This will facilitate our understanding of dVSMC 
pathophysiology and its role in vascular stiffness; it will also help us identify new targets 
for the development of novel therapeutic interventions to prevent cardiovascular diseases. 
Two methods can be used to obtain vascular smooth muscle cells: (1) a culture of the 
cells obtained using either the explant method (32, 63, 65, 90) or enzymatic dissociation 
(16, 32, 36) and (2) fresh isolation of single VSMCs using enzymatic digestion (82). The 
explant method is time consuming and requires several weeks. Some researchers have 
found it unsuitable for the small volume of mouse tissue (86). The culture of 
enzymatically dissociated SMCs was used successfully (59, 86). The enzymatic digestion 
to freshly isolate VSMCs is very expensive as it needs enzymes such as elastase, 
collagenase, and trypsin inhibitor. In contrast to the explant method, the cells obtained by 
enzymatic dissociation retain more of their differentiation characteristics (76). Our lab is 
well known for enzymatically isolating smooth muscle cells (contractile phenotype) from 
ferret tissue (25, 55, 56) in a unique way that enables use directly after isolation. To the 
best of my knowledge, this is the first time a method has been developed to isolate 
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dVSMCs from mice. Thus, the protocol used here is suitable for the small amount of 
mouse tissue and needs extra care during all steps. Most methods available for obtaining 
SMCs are for providing the synthetic phenotype, which is helpful for studying 
atherosclerosis pathophysiology (59, 86). One previous study described the behavior of 
SMCs in culture and how they resemble fibroblasts by the 9th day and do not respond to 
angiotensin II due to the loss of their contractile apparatus (16). Another study compared 
the morphological and biochemical features of aortic SMCs in-vivo and in-vitro (explants 
and subcultures) and concluded that significant differences exist between the two 
situations with the cells in culture having the same changes as those found in vascular 
diseases (32). Therefore, it is evident from the previous research on different sources of 
SMCs that cultured cells cannot be used to study the contractile phenotype. Contractile 
VSMCs are implicated in diseases such as aortic stiffness and hypertension. The 
dissociation of the contractile phenotype of smooth muscle cells was previously studied 
in non-vascular smooth muscle (4, 28, 84). Most of the time VSMCs are dissociated from 
the aorta, which, 1) because of its size can be easily dissected,  and 2) plays an important 
role in cardiovascular disease (91). Therefore, the aorta has been a favorite source of 
SMC in many studies (16, 90, 113). 
PE Increases Actin Polymerization in dVSMC  
When mouse dVSMCs were treated with the vasoconstrictor PE, actin polymerization 
increased significantly, supporting the role of actin polymerization as a regulator of 
dVSMC contractility in the mouse. Our lab was the first to study the effect of α-agonist 
(PE) on the F/G actin ratio; either at the cell level (using Phalloidin/DNase I costaining of 
		
36 
freshly isolated dVSMC) or at the tissue level (using differential ultracentrifugation), 
using a ferret model (55). Only a handful of other labs have made these measurements in 
other blood vessels. Thus, in this work, a modified protocol suitable for mouse tissue was 
created and successfully used for the first time at the cell and tissue levels of a mouse. 
Approximately 80% of actin in unstimulated dVSMC is F-actin, which can increase to 
90% with α-agonist stimulation (55), indicating that the actin cytoskeleton is a dynamic 
structure and not static. It can be regulated by stimuli that are involved in SMC 
contraction and relaxation (108). Previous work from our lab (55, 56) and two others (75, 
105) have shown that the actin cytoskeleton is remodeled in response to α-agonists 
stimulation of vascular tissue. However, another study reported that α-agonist (PE) is not 
associated with actin polymerization or cytoskeletal remodeling (30). Thus, controversy 
remains. The reason for the differing results could be due to different tissue, species, 
agonist or protocol used. 
  During contractile stimulation, the G-actin decreases while the F-actin increases 
in vascular and airway smooth muscle (5, 22, 47, 67). The increase in F/G ratio (actin 
polymerization) is an important determinant of force development (21). 
 
Conclusion and Future Directions 
Facing the need to isolate functional dVSMCs from mice for in-depth in vitro studies, I 
provide here a successful method for isolating dVSMC from mouse aorta. The protocol 
used here provides a good number of relaxed dVSMCs that contract to about 40% to 50% 
of their original length with agonist stimulation. Thus, this useful tool enables us to study 
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the molecular mechanism of cardiovascular diseases caused by dVSMC. By targeting 
specific pathways, especially those involving VSM phenotypic remodeling, we can 
discover novel medicine to treat or even prevent stiffness, aging, hypertension, and 
atherosclerosis. I also provide here a method by which actin polymerization can be 
assayed in mouse VSMC.  The current literature strongly suggests that actin 
polymerization may be a valuable drug target for new cardiovascular therapeutics. 
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